The expansion of the worldwide gastroparesis treatment market is anticipated to be driven by a rise in the number of pipeline products over the projected period. As a result, the medication candidates are given designations by regulatory agencies like the U.S. Food and Drug Administration (FDA). This will boost the amount of products in the pipeline, which will fuel market expansion. Over the projected period, it is anticipated that the discovery of novel treatments will fuel the growth of the worldwide gastroparesis treatment market. As a result, the development of fresh products will open up profitable opportunities for market participants and stimulate market growth. Patients with gastroparesis experienced a notable improvement in symptoms after receiving the innovative medication. Some of the novel techniques/agents being studied for gastroparesis include relamorelin, a prokinetic ghrelin agonist, velusetrag, and prucalopride, prokinetic serotonergic medications, aprepitant, an anti-emetic, and endoscopic pyloric myotomy procedures. As per Coherent Market Insights, the market for treatment gastroparesis worldwide is anticipated to reach US$ 8,061.9 million in 2022 and grow at a CAGR of 3.6% over the following five years (2022-2030).
Market Leaders in the treatment of Gastroparesis Industry:
1. Processa Pharmaceuticals, Inc.
The business, which has its headquarters in Hanover, Maryland, was established in October 2011. The Firm focuses on creating pharmaceutical medicines that are meant to increase patients' chances of surviving and their overall quality of life. On February 21, 2023, Processa Pharmaceuticals declared that the development of next-generation chemotherapy would receive priority.
2. Evoke Pharma
The business was established in 2007 and has its headquarters in Solana Beach, California. A gastrointestinal medicine is available from Evoke Pharma, Inc. for the treatment of individuals with diabetic gastroparesis and other gastrointestinal diseases and disorders. The business creates, makes, and sells pharmaceutical items. Jan 18, 2023 Evoke Pharma Announces Approval of an Abstract at the 2023 Annual Conference of the Academy of Managed Care Pharmacy.
3. Neurogastrx, Inc.
The firm was founded in 2012 and Greater Boston Area, East Coast, and New England are where the headquarters are located. As a biopharmaceutical business, Neurogastrx, Inc. creates biopharmaceutical therapeutics to treat gastrointestinal diseases. In June 2021, Neurogastrx announced a collaboration with Daewoong Pharmaceutical to develop fexuprazan for the treatment of GI disorders related to acidity.
4. Vanda Pharmaceuticals Inc.
The organisation was founded in 2002 and the company's headquarter is located in United States, Washington, D.C.The research and marketing of goods for the management of illnesses of the central nervous system are the main priorities of the biopharmaceutical business Vanda Pharmaceuticals Inc. Vanda released encouraging findings from the Phase III clinical research of Fanapt® in people with acute manic and mixed episodes related to bipolar I disorder in December 2022.
5. Teva Pharmaceutical Industries Ltd.
The corporation, founded in 1901, has its headquarters in Tel Aviv, Israel. Although its primary area of competence is in generic drugs, it also has some supplementary business interests in active pharmaceutical ingredients and, to a lesser extent, proprietary drugs. The aggressive climate targets set by Teva will have received external validation on January 19, 2023, according to the Science Based Targets initiative (SBTi). The federal opioids deal will move forward, Teva stated on January 9th, 2023, after getting broad backing from the states.
6. GlaxoSmithKline plc.
The business was established in 2000, and it is based in London, England. GSK manufactures drugs for conditions like diabetes, cancer, parasites, and mental health. The company reported receiving three unsolicited bids to purchase Unilever's Consumer Healthcare business segment in January 2022. In November 2022, GSK published encouraging Phase IIa study findings for a brand-new, first-in-class prospective therapy for tuberculosis patients.
7. Takeda Pharmaceutical Company Limited
The pharmaceutical business Takeda was established in 1781, and on January 29, 1925, it became a corporation. The company's main research interests include oncology, rare diseases, neurology, gastrointestinal, particle medicine, and vaccinations. The TYK2 Program Subsidiary of Nimbus Therapeutics was completely acquired by Takeda in February 2023. In October 2022, Takeda and Zedira and Dr. Falk Pharma signed a collaboration and licencing agreement to work together to create a first-in-class medication for celiac disease.
8. Atlantic Healthcare
The firm was founded in 2006 and Saffron Walden, Essex, England is home to Atlantic Healthcare.The primary business of Atlantic Healthcare plc is the development and marketing of specialised pharmaceuticals for use by patients in the hospital and speciality care sectors who are managed by doctors.
Definition: Gastroparesis is a disorder that interferes with your stomach's motility, or regular spontaneous movement of its muscles. Normally, food is moved through your digestive system by powerful muscular contractions.
